Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 10Phase 3 5Phase 1/2 5Phase NA 1Phase 4 1

Status

Terminated 2Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 30Gastrointestinal 23Genitourinary 14Breast 11Other solid neoplasm 8Lymphoid 8Sarcoma 6Gynecologic 6Dermatologic 6Tumor-Agnostic 5Other hematologic neoplasm 5CNS 5Head & Neck 4Endocrine 3NET 2Plasma cell 1Myeloid 1

Conditions

Neoplasms 3Neoplasm Metastasis 2

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × atezolizumab × Tumor-Agnostic × Clear all
NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05394337 2026-05-05

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

NCT05276284 2026-01-14

TEMPLE

Rigshospitalet, Denmark

Phase 1/2 Completed
18 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Terminated
33 enrolled
Tumor-Agnostic

Neoplasms

NCT03637764 2023-07-10

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Sanofi

Phase 1/2 Terminated
107 enrolled 30 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡